Trial Profile
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenously Administered REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 30 Apr 2019
Price :
$35
*
At a glance
- Drugs Garetosmab (Primary) ; Trevogrumab (Primary)
- Indications Musculoskeletal disorders
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 25 Apr 2019 Planned End Date changed from 4 Sep 2020 to 5 Nov 2020.
- 25 Apr 2019 Planned primary completion date changed from 26 Jun 2020 to 27 Aug 2020.
- 25 Apr 2019 Planned initiation date changed from 18 Feb 2019 to 19 Feb 2019.